Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Secondary to Myelodysplastic Syndrome

Autor: Linda Barber, Judith C. W. Marsh, ZiYi Lim, Victoria Potter, Ghulam J. Mufti, Michelle Kenyon, Abdel Dhouri, Pramila Krishnamurthy, Antonio Pagliuca, Robert Marcus, Aloysius Ho, Robin M. Ireland, Stephen Devereux, Hugues de Lavallade

Publikováno v: Potter, V T, Krishnamurthy, P, Barber, L D, Lim, Z, Kenyon, M, Ireland, R M, de Lavallade, H, Dhouri, A, Marsh, J C W, Marcus, R, Devereux, S, Ho, A, Pagliuca, T & Mufti, G J 2014, ' Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Secondary to Myelodysplastic Syndrome ', BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 20, no. 1, pp. 111-117 . https://doi.org/10.1016/j.bbmt.2013.10.021

Allogeneic hematopoietic stem cell transplantation (HSCT) with reduced-intensity conditioning (RIC) offers a potential cure for patients with myelodysplastic syndrome (MDS) who are ineligible for standard-intensity regimens. Previously published data

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2790ab205c767f5f54dc0ea08465095b